Article Text
Abstract
Aim: To determine the duration of residence of triamcinolone in the vitrectomised eye.
Methods: 23 eyes of 23 patients underwent intravitreal injection of high dose (20 mg) decanted triamcinolone acetonide (Kenalog) at the conclusion of vitrectomy surgery or in previously vitrectomised eyes with macular oedema from diabetes, uveitis, cataract surgery, or other surgery.
Results: The median time to disappearance of triamcinolone in the vitrectomised eye was 113 days (95% confidence interval (CI) 85 to 191). In the phakic eyes the median time to disappearance was 191 days (95% CI 148 to 191). In the pseudophakic eyes the median time to disappearance was 102 days (95% CI 85 to 113). This difference was not significant (p = 0.12). There were no cases of endophthalmitis or severe inflammatory reaction. Five eyes (22%) experienced intraocular pressure rise ⩾10 mm Hg.
Conclusions: High dose decanted intravitreal triamcinolone has a median residence time of 113 days in the vitrectomised eye. Although this appears to be shorter than in the non-vitrectomised eye, this study suggests that a sufficient duration of action will be present to be clinically useful.
- ARMD, age related macular degeneration
- IOP, intraocular pressure
- POAG, primary open angle glaucoma
- diabetes
- macular degeneration
- macular oedema
- triamcilone
- vitreous injection
- ARMD, age related macular degeneration
- IOP, intraocular pressure
- POAG, primary open angle glaucoma
- diabetes
- macular degeneration
- macular oedema
- triamcilone
- vitreous injection
Statistics from Altmetric.com
Footnotes
-
Sponsoring organisation: NIH EYO 7366 (WRF).
-
Proprietary interests: none.
Linked Articles
- BJO at a glance